Core Viewpoint - The controlling shareholder of Xuantai Pharmaceutical, Shanghai Lianhe Investment Co., Ltd., has voluntarily committed not to reduce its shareholding in the company for 24 months starting from August 25, 2025, to enhance investor confidence and maintain market stability [1][2]. Group 1: Shareholder Commitment - The commitment from the controlling shareholder comes at a critical time when the company's original shareholders' restricted shares are about to be unlocked, alleviating market concerns about large-scale share reductions [2]. - On August 25, 2023, a total of 311 million shares will be unlocked, accounting for 68.61% of the total share capital, with Lianhe Investment holding 233 million shares, representing 75% of the unlocked shares [2]. - The actual reducible shares will be significantly reduced to 7.8 million shares, effectively easing potential liquidity pressure from the concentrated unlocking [2]. Group 2: Business Strengths - Xuantai Pharmaceutical's long-term outlook is supported by its robust core strategic business and the competitive barriers of its high-end formulation technology [3]. - The company focuses on high-end generic drugs and has developed a leading drug chemical formulation platform in China, with a strong emphasis on R&D and technological innovation [3]. - The product portfolio includes 16 approved products by the end of 2024, with several being first generics in both domestic and international markets [3]. Group 3: CRO/CMO Performance - In the CRO/CMO sector, Xuantai Pharmaceutical has successfully assisted in the approval and commercialization of multiple innovative drugs, with over 100 projects completed for global clients [4]. - The company has established partnerships with several well-known pharmaceutical companies, enhancing its market presence and service capabilities [4]. Group 4: Shareholder Returns - Xuantai Pharmaceutical has consistently prioritized shareholder returns, implementing a stable and continuous dividend policy, with a total cash dividend of 74.36 million yuan since its listing in 2022 [5][6]. - The company completed a share buyback in February 2025, repurchasing 4.3361 million shares, which represents 0.96% of the total share capital, further demonstrating its commitment to enhancing shareholder value [6]. - The controlling shareholder's commitment not to reduce holdings is seen as a strong vote of confidence in the company's long-term strategy and management team, reinforcing the company's positive image in the capital market [6].

公告显示，基于对公司未来发展前景的信心和对公司长期价值的认可，同时为增强广大投资者信心，切 实维护投资者权益和资本市场稳定，公司控股股东联和投资自愿承诺，自8月25日起24个月内不通过集 中竞价交易、大宗交易等方式减持其所持有的公司股份。 北京商报讯(记者丁宁)8月17日晚间，宣泰医药(688247)发布公告称，公司于8月15日收到公司控股股东 上海联和投资有限公司(以下简称"联和投资")出具的《关于自愿承诺未来24个月不减持上海宣泰医药科 技股份有限公司股份的承诺函》。 ...

2024年1至12月份，宣泰医药的营业收入构成为：医药制造业占比99.89%，其他业务占比0.11%。 （文章来源：每日经济新闻） 宣泰医药（SH 688247，收盘价：12.35元）8月17日晚间发布公告称，公司限售股份约3.11亿股将于2025 年8月25日解禁并上市流通，占公司总股本比例为68.61%。 ...

证券代码：688247 证券简称：宣泰医药 公告编号：2025-032 上海宣泰医药科技股份有限公司 首次公开发行部分限售股上市流通公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次股票上市类型为首发限售股份；股票认购方式为网下，上市股数为 311,018,400股。 本次股票上市流通总数为311,018,400股。 本次股票上市流通日期为2025 年 8 月 25 日。 一、本次上市流通的限售股类型 根据中国证券监督管理委员会《关于同意上海宣泰医药科技股份有限公司首 次公开发行股票注册的批复》（证监许可[2022]1383 号），上海宣泰医药科技股份有 限公司（以下简称"公司"、"宣泰医药"）获准向社会公开发行人民币普通股（A） 股 45,340,000.00 股，并于 2022 年 8 月 25 日在上海证券交易所科创板上市，发行 完成后公司总股本为 453,340,000 股，其中有限售条件流通股为 412,430,080 股， 无限售条件流通股为 40,909,920 股。 本次上市流通的限 ...

国泰海通证券股份有限公司 国泰海通证券股份有限公司（以下简称"国泰海通"、"保荐机构"）作 为上海宣泰医药科技股份有限公司（以下简称"宣泰医药"或"公司"）首次 公开发行股票并在科创板上市的保荐机构，根据《证券发行上市保荐业务管理 办法》《上海证券交易所科创板股票上市规则》《上海证券交易所科创板上市 公司自律监管指引第 1 号——规范运作》等有关规定，对宣泰医药首次公开发 行部分限售股上市流通事项进行了审慎核查，具体情况如下： 一、本次上市流通的限售股类型 根据中国证券监督管理委员会《关于同意上海宣泰医药科技股份有限公司首 次公开发行股票注册的批复》（证监许可[2022]1383 号），公司获准向社会公开 发行人民币普通股（A）股 45,340,000.00 股，并于 2022 年 8 月 25 日在上海证 券交易所科创板上市，发行完成后公司总股本为 453,340,000 股，其中有限售条 件流通股为 412,430,080 股，无限售条件流通股为 40,909,920 股。 本次上市流通的限售股为公司首次公开发行的部分限售股，限售股股东数量 为 5 名，限售期为自公司股票上市之日起 36 个月，该部分限售 ...

证券代码：688247 证券简称：宣泰医药 公告编号：2025-031 上海宣泰医药科技股份有限公司 关于控股股东自愿承诺不减持公司股份的公告 公司董事会将对上述承诺事项的履行情况进行持续监督并及时履行信息披 露义务。 特此公告。 上海宣泰医药科技股份有限公司董事会 2025 年 8 月 18 日 上海宣泰医药科技股份有限公司（以下简称"公司"）于 2025 年 8 月 15 日收到公司控股股东上海联和投资有限公司（以下简称"联和投资"）出具的《关 于自愿承诺未来 24 个月不减持上海宣泰医药科技股份有限公司股份的承诺函》。 现将相关情况公告如下： 基于对公司未来发展前景的信心和对公司长期价值的认可，同时为增强广大 投资者信心，切实维护投资者权益和资本市场稳定，公司控股股东联和投资自愿 承诺，自 2025 年 8 月 25 日起 24 个月内（2025 年 8 月 25 日至 2027 年 8 月 24 日）不通过集中竞价交易、大宗交易等方式减持其所持有的公司股份。在上述承 诺期间，如发生资本公积转增股本、派送股票红利、配股等产生新增股份，亦遵 守该不减持承诺。 截至本公告披露日，公司控股股东联和投资持股情况 ...

Core Viewpoint - The controlling shareholder of Xuantai Pharmaceutical, Shanghai Lianhe Investment Co., Ltd., has voluntarily committed not to reduce its shareholding for 24 months starting from August 25, 2025, to enhance investor confidence and maintain market stability [1][4] Group 1: Shareholder Commitment - The commitment not to reduce shareholding is based on confidence in Xuantai Pharmaceutical's future development and long-term value recognition [1] - On August 25, 2023, a total of 311 million shares of Xuantai Pharmaceutical will be unlocked, accounting for 68.61% of the total share capital, with Lianhe Investment holding 233 million shares, representing 75% of the unlocked shares [1] Group 2: Business Development and Competitive Edge - Xuantai Pharmaceutical's controlling shareholder is optimistic due to the robust development of the company's core strategic business and the broad industry prospects [2] - The company has established three major technology platforms for high-barrier products in the generic drug sector, including "insoluble drug solubilization technology platform," "controlled-release drug formulation R&D platform," and "fixed-dose combination formulation R&D platform" [2] - By the end of 2024, Xuantai Pharmaceutical is expected to have 16 approved products, including several first-generic products domestically and internationally [2] Group 3: CRO/CMO Performance - In the CRO/CMO sector, Xuantai Pharmaceutical has successfully assisted in the approval of multiple innovative drugs and has developed over 100 innovative drug formulations [3] - The company has established partnerships with several listed companies and well-known pharmaceutical enterprises, providing CMO services for eight approved new drug products [3] Group 4: Investor Relations and Dividends - Xuantai Pharmaceutical prioritizes cash dividends to reward shareholders, having distributed a total of 74.36 million yuan in cash dividends since its listing in 2022, with plans for mid-term dividends in 2024 [3] - The commitment from the controlling shareholder serves as a strong vote of confidence in the company's existing development strategy and management team [4]

Core Viewpoint - The company, Xuantai Pharmaceutical (688247), announced a commitment from its controlling shareholder, Lianhe Investment, to not reduce its shareholding through various trading methods for a period of 24 months, starting from August 25, 2025, to enhance investor confidence and maintain market stability [1] Summary by Relevant Categories Company Commitment - Lianhe Investment, the controlling shareholder, voluntarily pledged to refrain from selling its shares in the company through centralized bidding or block trading for 24 months [1] Investor Confidence - The commitment aims to bolster investor confidence and protect the rights of investors, reflecting the company's confidence in its future development prospects and long-term value [1]

Group 1 - The company announced the approval of a proposal to use part of its idle raised funds for cash management, with a limit not exceeding 80 million RMB [2] - The decision was made during the 15th meeting of the second board of directors' audit committee and the 17th board meeting held on August 8, 2025 [2] - The usage period for the funds is set for 12 months from the date of board approval, allowing for rolling use within the specified limit and timeframe [2]

使用部分闲置募集资金进行现金管理的核查意见 国泰海通证券股份有限公司（以下简称"国泰海通"或"保荐机构"）作为 上海宣泰医药科技股份有限公司（以下简称"宣泰医药"或"公司"）首次公开 发行股票并上市持续督导保荐机构，根据《证券发行上市保荐业务管理办法》《上 市公司募集资金监管规则》《上海证券交易所科创板股票上市规则》《上海证券 交易所科创板上市公司自律监管指引第 1 号——规范运作》等有关规定，对公司 使用部分闲置募集资金（含超募资金）进行现金管理的事项进行了核查，具体情 况如下： 一、募集资金基本情况 国泰海通证券股份有限公司 关于上海宣泰医药科技股份有限公司 根据中国证券监督管理委员会《关于同意上海宣泰医药科技股份有限公司首 次公开发行股票注册的批复》（证监许可[2022]1383 号），公司获准向社会公开 发行人民币普通股（A）股 45,340,000.00 股，发行价格为 9.37 元/股，募集资金 总额为人民币 42,483.58 万元，扣除与发行相关的费用（不含增值税）人民币 4,761.77 万元，实际募集资金净额为人民币 37,721.81 万元。 上述资金到位情况经上会会计师事务所（特殊普通 ...